BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 37977350)

  • 1. Elevated 2-oxoglutarate antagonizes DNA damage responses in cholangiocarcinoma chemotherapy through regulating aspartate beta-hydroxylase.
    Nagaoka K; Bai X; Liu D; Cao K; Mulla J; Ji C; Chen H; Nisar MA; Bay A; Mueller W; Hildebrand G; Gao JS; Lu S; Setoyama H; Tanaka Y; Wands JR; Huang CK
    Cancer Lett; 2024 Jan; 580():216493. PubMed ID: 37977350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aspartate beta-hydroxylase promotes cholangiocarcinoma progression by modulating RB1 phosphorylation.
    Huang CK; Iwagami Y; Zou J; Casulli S; Lu S; Nagaoka K; Ji C; Ogawa K; Cao KY; Gao JS; Carlson RI; Wands JR
    Cancer Lett; 2018 Aug; 429():1-10. PubMed ID: 29733964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-Tumor Effects of Second Generation β-Hydroxylase Inhibitors on Cholangiocarcinoma Development and Progression.
    Huang CK; Iwagami Y; Aihara A; Chung W; de la Monte S; Thomas JM; Olsen M; Carlson R; Yu T; Dong X; Wands J
    PLoS One; 2016; 11(3):e0150336. PubMed ID: 26954680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Aspartate Beta-Hydroxylase with the Small Molecule Inhibitor MO-I-1182 Suppresses Cholangiocarcinoma Metastasis.
    Nagaoka K; Ogawa K; Ji C; Cao KY; Bai X; Mulla J; Cheng Z; Wands JR; Huang CK
    Dig Dis Sci; 2021 Apr; 66(4):1080-1089. PubMed ID: 32445050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ten-Eleven Translocation 1 Promotes Malignant Progression of Cholangiocarcinoma With Wild-Type Isocitrate Dehydrogenase 1.
    Bai X; Zhang H; Zhou Y; Nagaoka K; Meng J; Ji C; Liu D; Dong X; Cao K; Mulla J; Cheng Z; Mueller W; Bay A; Hildebrand G; Lu S; Wallace J; Wands JR; Sun B; Huang CK
    Hepatology; 2021 May; 73(5):1747-1763. PubMed ID: 32740973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aspartate β-hydroxylase (ASPH) Accelerates Intrahepatic Cholangiocarcinoma Metastasis
    Zou Y; Lin J; Liu J; Zhang F; Yang T; Gong J; Jiang T; Zuo J; Song R; Shen H; Shen F; Li J
    Curr Protein Pept Sci; 2023; 24(5):436-446. PubMed ID: 37132101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salubrinal Enhances Doxorubicin Sensitivity in Human Cholangiocarcinoma Cells Through Promoting DNA Damage.
    Yu W; Xiang Y; Luo G; Zhao X; Xiao B; Cheng Y; Feng C; Duan C; Xia X; Wong VKW; Dai R
    Cancer Biother Radiopharm; 2018 Aug; 33(6):258-265. PubMed ID: 29957018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced expression of ten-eleven translocation 1 reverses gemcitabine resistance in cholangiocarcinoma accompanied by a reduction in P-glycoprotein expression.
    Wang C; Ye H; Zhang L; Cheng Y; Xu S; Zhang P; Zhang Z; Bai J; Meng F; Zhong L; Shi G; Li H
    Cancer Med; 2019 Mar; 8(3):990-1003. PubMed ID: 30784212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long non-coding RNA LINC00665 promotes gemcitabine resistance of Cholangiocarcinoma cells via regulating EMT and stemness properties through miR-424-5p/BCL9L axis.
    Lu M; Qin X; Zhou Y; Li G; Liu Z; Geng X; Yue H
    Cell Death Dis; 2021 Jan; 12(1):72. PubMed ID: 33436545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The therapeutic effect of KSP inhibitors in preclinical models of cholangiocarcinoma.
    Shi Y; Cui X; Jiang T; Pan Y; Lin Y; Feng X; Ding Z; Yang C; Tan Y; Wang H; Dong L
    Cell Death Dis; 2022 Sep; 13(9):799. PubMed ID: 36123339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular perturbations in cholangiocarcinoma: Is it time for precision medicine?
    Braconi C; Roessler S; Kruk B; Lammert F; Krawczyk M; Andersen JB
    Liver Int; 2019 May; 39 Suppl 1():32-42. PubMed ID: 30829432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Micro-RNA-130a-3p Regulates Gemcitabine Resistance via PPARG in Cholangiocarcinoma.
    Asukai K; Kawamoto K; Eguchi H; Konno M; Asai A; Iwagami Y; Yamada D; Asaoka T; Noda T; Wada H; Gotoh K; Nishida N; Satoh T; Doki Y; Mori M; Ishii H
    Ann Surg Oncol; 2017 Aug; 24(8):2344-2352. PubMed ID: 28560603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of potential targets to enhance the sensitivity of cholangiocarcinoma cells to anticancer drugs.
    Sanchon-Sanchez P; Briz O; Macias RIR; Abad M; Sanchez-Martin A; Marin JJG; Lozano E
    Biomed Pharmacother; 2023 Dec; 168():115658. PubMed ID: 37832404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinetic parameters of human aspartate/asparagine-β-hydroxylase suggest that it has a possible function in oxygen sensing.
    Brewitz L; Tumber A; Schofield CJ
    J Biol Chem; 2020 Jun; 295(23):7826-7838. PubMed ID: 32107312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA Damage Response Inhibitors in Cholangiocarcinoma: Current Progress and Perspectives.
    Gönül Geyik Ö; Anichini G; Ulukaya E; Marra F; Raggi C
    Cells; 2022 Apr; 11(9):. PubMed ID: 35563769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infigratinib for cholangiocarcinoma.
    Sadeghi S
    Drugs Today (Barc); 2022 Jul; 58(7):327-334. PubMed ID: 35851868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunization with aspartate-β-hydroxylase-loaded dendritic cells produces antitumor effects in a rat model of intrahepatic cholangiocarcinoma.
    Noda T; Shimoda M; Ortiz V; Sirica AE; Wands JR
    Hepatology; 2012 Jan; 55(1):86-97. PubMed ID: 21898484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic Treatment for Cholangiocarcinoma.
    Sookprasert A; Wirasorn K; Chindaprasirt J; Watcharenwong P; Sanlung T; Putraveephong S
    Recent Results Cancer Res; 2023; 219():223-244. PubMed ID: 37660335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma.
    Ewald F; Grabinski N; Grottke A; Windhorst S; Nörz D; Carstensen L; Staufer K; Hofmann BT; Diehl F; David K; Schumacher U; Nashan B; Jücker M
    Int J Cancer; 2013 Nov; 133(9):2065-76. PubMed ID: 23588885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extracellular Signal-Regulated Kinase 5 Regulates the Malignant Phenotype of Cholangiocarcinoma Cells.
    Gentilini A; Lori G; Caligiuri A; Raggi C; Di Maira G; Pastore M; Piombanti B; Lottini T; Arcangeli A; Madiai S; Navari N; Banales JM; Di Matteo S; Alvaro D; Duwe L; Andersen JB; Tubita A; Tusa I; Di Tommaso L; Campani C; Rovida E; Marra F
    Hepatology; 2021 Oct; 74(4):2007-2020. PubMed ID: 33959996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.